Skip to main content
Advanced Accelerator Applications' Lutathera approved in Canada
2/18/2019

Health Canada has given Advanced Accelerator Applications approval to market its Lutathera, or lutetium-177 DOTATATE, as treatment for gastroenteropancreatic neuroendocrine tumors among adults with progressive disease.

Full Story: